2.35
-0.20 (-7.84%)
| 前收盘价格 | 2.55 |
| 收盘价格 | 2.60 |
| 成交量 | 417,043 |
| 平均成交量 (3个月) | 625,731 |
| 市值 | 22,457,164 |
| 价格/销量 (P/S) | 2.72 |
| 股市价格/股市净资产 (P/B) | 7.77 |
| 52周波幅 | |
| 利润日期 | 25 Jul 2023 - 31 Jul 2023 |
| 营业毛利率 | -14.74% |
| 营业利益率 (TTM) | 7.86% |
| 稀释每股收益 (EPS TTM) | 1.05 |
| 季度收入增长率 (YOY) | 54.00% |
| 总债务/股东权益 (D/E MRQ) | 186.77% |
| 流动比率 (MRQ) | 2.79 |
| 资产报酬率 (ROA TTM) | 0.98% |
| 股东权益报酬率 (ROE TTM) | -34.57% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | Alimera Sciences, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | 0.17 |
|
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 5.34% |
| 机构持股比例 | 86.54% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合